The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 18, 2025

Filed:

Oct. 13, 2021
Applicant:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Inventors:

Jamie Orengo, Cortlandt Manor, NY (US);

Andrew J. Murphy, Croton-on-Hudson, NY (US);

Assignee:

REGENERON PHARMACEUTICALS, INC., Tarrytown, NY (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/18 (2006.01); A61K 39/00 (2006.01); A61K 39/12 (2006.01); A61K 39/35 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07K 16/46 (2006.01);
U.S. Cl.
CPC ...
C07K 16/18 (2013.01); A61K 39/12 (2013.01); A61K 39/35 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07K 16/468 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/5252 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/34 (2013.01); C07K 2317/565 (2013.01); C07K 2317/92 (2013.01); C12N 2760/16334 (2013.01);
Abstract

The present invention provides antibodies that bind to the cat allergen, Fel d1, compositions comprising the antibodies, nucleic acids encoding the antibodies and methods of use of the antibodies. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Fel d1. The antibodies of the invention are useful for binding to the Fel d1 allergen in vivo, thus preventing binding of the Fel d1 allergen to pre-formed IgE on the surface of mast cells or basophils. In doing so, the antibodies act to prevent the release of histamine and other inflammatory mediators from mast cells and/or basophils, thus ameliorating the untoward response to the cat allergen in sensitized individuals. The antibodies of the invention may also be useful for diagnostic purposes to determine if a patient is allergic to the Fel d1 cat allergen.


Find Patent Forward Citations

Loading…